|
1.
|
Nador RG, Cesarman E, Chadburn A, et al:
Primary effusion lymphoma: a distinct clinicopathologic entity
associated with the Kaposi’s sarcoma-associated herpes virus.
Blood. 88:645–656. 1996.
|
|
2.
|
Chen YB, Rahemtullah A and Hochberg E:
Primary effusion lymphoma. Oncologist. 12:569–576. 2007.
|
|
3.
|
Cesarman E, Chang Y, Moore PS, et al:
Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in
AIDS-related body-cavity-based lymphomas. N Engl J Med.
332:1186–1191. 1995.
|
|
4.
|
Lee CK: Evolving role of radiation therapy
for hematologic malignancies. Hematol Oncol Clin North Am.
20:471–503. 2006.
|
|
5.
|
Gustavsson A, Osterman B and
Cavallin-Stahl E: A systematic overview of radiation therapy
effects in non-Hodgkin’s lymphoma. Acta Oncol. 42:605–619.
2003.
|
|
6.
|
Renne R, Zhong W, Herndier B, et al: Lytic
growth of Kaposi’s sarcoma-associated herpesvirus (human
herpesvirus 8) in culture. Nat Med. 2:342–346. 1996.
|
|
7.
|
Cesarman E, Moore PS, Rao PH, et al: In
vitro establishment and characterization of two acquired
immunodeficiency syndrome-related lymphoma cell lines (BC-1 and
BC-2) containing Kaposi’s sarcoma-associated herpesvirus-like
(KSHV) DNA sequences. Blood. 86:2708–2714. 1995.
|
|
8.
|
Arvanitakis L, Mesri EA, Nador RG, et al:
Establishment and characterization of a primary effusion (body
cavity-based) lymphoma cell line (BC-3) harboring kaposi’s
sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of
Epstein-Barr virus. Blood. 88:2648–2654. 1996.
|
|
9.
|
Sellins KS and Cohen JJ: Gene induction by
gamma-irradiation leads to DNA fragmentation in lymphocytes. J
Immunol. 139:3199–3206. 1987.
|
|
10.
|
Nicoletti I, Migliorati G, Pagliacci MC,
et al: A rapid and simple method for measuring thymocyte apoptosis
by propidium iodide staining and flow cytometry. J Immunol Methods.
139:271–279. 1991.
|
|
11.
|
Shinkai Y, Rathbun G, Lam KP, et al:
RAG-2-deficient mice lack mature lymphocytes owing to inability to
initiate V(D)J rearrangement. Cell. 68:855–867. 1992.
|
|
12.
|
Park SY, Saijo K, Takahashi T, et al:
Developmental defects of lymphoid cells in Jak3 kinase-deficient
mice. Immunity. 3:771–782. 1995.
|
|
13.
|
Attia MA and Weiss DW: Immunology of
spontaneous mammary carcinomas in mice. V. Acquired tumor
resistance and enhancement in strain A mice infected with mammary
tumor virus. Cancer Res. 26:1787–1800. 1966.
|
|
14.
|
Harada H, Suzu S, Ito T, et al: Selective
expansion and engraftment of human CD16+ NK cells in NOD/SCID mice.
Eur J Immunol. 35:3599–3609. 2005.
|
|
15.
|
Vermes I, Haanen C, Steffens-Nakken H, et
al: A novel assay for apoptosis. Flow cytometric detection of
phosphatidylserine expression on early apoptotic cells using
fluorescein labelled Annexin V. J Immunol Methods. 184:39–51.
1995.
|
|
16.
|
Boulanger E, Daniel MT, Agbalika F, et al:
Combined chemotherapy including high-dose methotrexate in
KSHV/HHV8-associated primary effusion lymphoma. Am J Hematol.
73:143–148. 2003.
|
|
17.
|
Pauley JL, Panetta JC, Schmidt J, et al:
Late-onset delayed excretion of methotrexate. Cancer Chemother
Pharmacol. 54:146–152. 2004.
|
|
18.
|
Waddington TW and Aboulafia DM: Failure to
eradicate AIDS-associated primary effusion lymphoma with high-dose
chemotherapy and autologous stem cell reinfusion: case report and
literature review. AIDS Patient Care STDS. 18:67–73. 2004.
|
|
19.
|
Liu L, Eby MT, Rathore N, et al: The human
herpes virus 8-encoded viral FLICE inhibitory protein physically
associates with and persistently activates the Ikappa B kinase
complex. J Biol Chem. 277:13745–13751. 2002.
|
|
20.
|
Chaudhary PM, Jasmin A, Eby MT, et al:
Modulation of the NF-kappa B pathway by virally encoded death
effector domains-containing proteins. Oncogene. 18:5738–5746.
1999.
|
|
21.
|
Sun Q, Matta H and Chaudhary PM: The human
herpes virus 8-encoded viral FLICE inhibitory protein protects
against growth factor withdrawal-induced apoptosis via NF-kappa B
activation. Blood. 101:1956–1961. 2003.
|
|
22.
|
Mayo MW and Baldwin AS: The transcription
factor NF-kappaB: control of oncogenesis and cancer therapy
resistance. Biochim Biophys Acta. 1470:M55–M62. 2000.
|
|
23.
|
Keller SA, Schattner EJ and Cesarman E:
Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary
effusion lymphoma cells. Blood. 96:2537–2542. 2000.
|
|
24.
|
Dabaghmanesh N, Matsubara A, Miyake A, et
al: Transient inhibition of NF-kappaB by DHMEQ induces cell death
of primary effusion lymphoma without HHV-8 reactivation. Cancer
Sci. 100:737–746. 2009.
|
|
25.
|
Keller SA, Hernandez-Hopkins D, Vider J,
et al: NF-kappaB is essential for the progression of KSHV- and
EBV-infected lymphomas in vivo. Blood. 107:3295–3302.
2006.
|
|
26.
|
Takahashi-Makise N, Suzu S, Hiyoshi M, et
al: Biscoclaurine alkaloid cepharanthine inhibits the growth of
primary effusion lymphoma in vitro and in vivo and
induces apoptosis via suppression of the NF-kappaB pathway. Int J
Cancer. 125:1464–1472. 2009.
|
|
27.
|
McConkey D, Nawrocki ST and Andtbacka R:
Velcade displays promising activity in primary effusion lymphoma
cells. Cancer Biol Ther. 4:491–492. 2005.
|
|
28.
|
An J, Sun Y, Fisher M, et al: Antitumor
effects of bortezomib (PS-341) on primary effusion lymphomas.
Leukemia. 18:1699–1704. 2004.
|
|
29.
|
Boulanger E, Meignin V and Oksenhendler E:
Bortezomib (PS-341) in patients with human herpesvirus 8-associated
primary effusion lymphoma. Br J Haematol. 141:559–561. 2008.
|
|
30.
|
Gospodarowicz M: Radiotherapy in
non-Hodgkin lymphomas. Ann Oncol. 19(Suppl 4): iv47–iv50. 2008.
|
|
31.
|
Cassoni A, Ali U, Cave J, et al: Remission
after radiotherapy for a patient with chemotherapy-refractory
HIV-associated primary effusion lymphoma. J Clin Oncol.
26:5297–5299. 2008.
|
|
32.
|
Dubray B, Breton C, Delic J, et al: In
vitro radiation-induced apoptosis and early response to
low-dose radiotherapy in non-Hodgkin’s lymphomas. Radiother Oncol.
46:185–191. 1998.
|
|
33.
|
Bankert RB, Hess SD and Egilmez NK: SCID
mouse models to study human cancer pathogenesis and approaches to
therapy: potential, limitations, and future directions. Front
Biosci. 7:c44–c62. 2002.
|
|
34.
|
Bankert RB, Egilmez NK and Hess SD:
Human-SCID mouse chimeric models for the evaluation of anti-cancer
therapies. Trends Immunol. 22:386–393. 2001.
|
|
35.
|
Shultz LD, Ishikawa F and Greiner DL:
Humanized mice in translational biomedical research. Nat Rev
Immunol. 7:118–130. 2007.
|
